Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER
- 6 February 1996
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 99 (2), 209-215
- https://doi.org/10.1016/0304-3835(95)04066-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ERCancer Letters, 1994
- Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomasBritish Journal of Cancer, 1994
- Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerBreast Cancer Research and Treatment, 1993
- Involvement of Urokinase and its Receptor in the Invasiveness of Human Prostatic Carcinoma Cell LinesCancer Communications, 1991
- Anti-Epidermal Growth Factor Receptor Antibodies Inhibit the Autocrine-Stimulated Growth of MDA-468 Human Breast Cancer CellsMolecular Endocrinology, 1989
- Modulation of Plasminogen Activator Systems by Matrix Components in Two Breast Cancer Cell Lines: MCF-7 and MDA-MB-231JNCI Journal of the National Cancer Institute, 1989
- Epidermal Growth Factor Receptor Gene Expression in Estrogen Receptor-Positive and Negative Human Breast Cancer Cell LinesMolecular Endocrinology, 1987
- Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cellsBreast Cancer Research and Treatment, 1986
- Plasminogen Activators, Tissue Degradation, and CancerAdvances in Cancer Research, 1985
- Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substratesAnalytical Biochemistry, 1980